Rgenix

Rgenix

Rgenix

Rgenix is a preclinical stage pharmaceutical company with a mission to develop the world's first cancer therapies designed specifically to target cancer metastasis, the main cause of mortality in cancer patients.
Founded
2010
Raised
$73M
Follow us
Alexa global traffic share
Latest funding
$40,000,000
Venture capital (Series C) - 2018
WuXi AppTec’s Corporate Venture Fund Oceanpine Capital Lepu Medical
$33,000,000
Venture capital (Series B) - 2016
Sofinnova Partners Novo A/S
Team Size
2
Employees
$40,000,000 Venture capital (Series C)
PE HUB , StartupWorld

Rgenix grabs $40 mln Series C

$33,000,000 Venture capital (Series B)
Xconomy , FinSMEs

Rgenix Raises $33M, Preps Cancer Trial For Drug Shelved By GSK

Health Funding Science
Xconomy

In New York, Rgenix Rises From Rockefeller and Takes Aim at Cancer

Health Funding Science